Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant
Identifieur interne : 002043 ( Main/Merge ); précédent : 002042; suivant : 002044Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant
Auteurs : Susan B. Dillon [États-Unis] ; Sandra G. Demuth [États-Unis] ; Mark A. Schneider [États-Unis] ; Cynthia B. Weston [États-Unis] ; Christopher S. Jones [États-Unis] ; James F. Young [États-Unis] ; Miller Scott [États-Unis] ; Pradip K. Bhatnaghar [États-Unis] ; Stephen Locastro [États-Unis] ; Nabil Hanna [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 1992.
English descriptors
- Teeft :
- Active immunization, Adjuvant, Aluminium, Aluminium adjuvant, Aluminium hydroxide, Aluminium hydroxide adjuvant, Amino acids, Antibody responses, Antigenic drift, Antiviral memory, Assay, Baylor college, Bold type, Booster injection, Braciale, Cb6f, Cell response, Chromium release assay, Complete adjuvant, Control group, Control mice, Cytotoxic, Effector, Effector cells, Eliciting protection, Epitope, Epitope peptide, Escherichia coli, Human influenza, Hydroxide, Immune, Immune response, Immune sera, Immunization, Immunol, Influenza, Influenza vaccine, Influenza virus cytotoxic, Influenza virus vaccines, Ldso doses, Lethal challenge, Limited number, Lymph node cells, Lymphocyte, Major histocompatibility, Mice vaccinated, Microtitre wells, Monoclonal antibody, Mouse, Neutralizing, Neutralizing antibodies, Neutralizing antibody, Other studies, Outbred mice, Passive transfer, Peptide, Percentage lysis, Protective efficacy, Protective immunity, Protein, Protein control, Recombinant, Recombinant influenza vaccine, Recombinant nucleoprotein, Single injection, Soluble proteins, Spleen, Splenic, Splenic memory, Subunit, Synthetic peptide, Target cells, Target ratio, Target ratio figure, Third injection, Uninfected target cells, Unpublished results, Vaccination, Vaccine, Various times, Virus, Virus challenge, Weeks post.
Abstract
Abstract: Induction of class I MHC-restricted cytotoxic T lymphocyte (CTL) responses by soluble proteins or peptides requires complex adjuvants or carrier systems which are not licensed for use with human vaccines. The data presented in this report show that vaccination with a highly purified recombinant influenza protein antigen in aluminium hydroxide adjuvant, the only adjuvant currently licensed for clinical use, elicited class I restricted CTL and protection from lethal challenge with H1N1 and H2N2 viruses. The antigen (D protein, SK&F 106160) is produced by expression of H1N1 influenza virus-derived cDNA (strain A/PR/8/34) in Escherichia coli, and is composed of the first 81 N-terminal amino acids (aa) of the non-structural protein 1 (NS1) fused via a nine nucleotide non-viral linker sequence to the 157 C-terminal aa of the haemagglutinin 2 subunit (HA2). Previous work by Kuwano et al demonstrated that in vitro stimulation of spleen cells from influenza virus-primed mice, with a partially purified preparation of the D protein, selected for CD8− CTL clones which facilitated lung clearance of H1N1 and H2N2 viruses. In the current study, these results were extended by studying the responses of mice actively immunized with highly purified D protein in the presence or absence of adjuvants. Vaccination of CB6F1 (H-2d × b) mice with D protein in aluminium hydroxide or Freund's complete adjuvant generated H1N1 cross-reactive, H-2d-restricted, CD8+ CTL directed against an immunodominant HA2 epitope (aa 189–199). D protein without adjuvant did not elicit CTL, regardless of the route of injection. However, long-lived (>6 months) splenic memory CTL were elicited by boosting mice intraperitoneally (i.p.) with the D protein in the absence of adjuvant. In mice injected subcutaneously with D protein in aluminium hydroxide at weeks 0 and 3, survival was increased relative to controls up to 16 weeks beyond the second vaccination, after which time additional boosting was required for protection. Studies in H-2b and H-2k mice vaccinated with the D protein showed that induction of CD4+ T-cell or antibody responses, in the absence of CD8+ CTL, did not correlate with protection. Passive transfer of immune sera from CB6F1 mice was also not protective. This prototype H1N1 recombinant subunit vaccine in aluminium adjuvant should directly address the feasibility of achieving a protective cell-mediated immune response in human influenza.
Url:
DOI: 10.1016/0264-410X(92)90369-U
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000188
- to stream Istex, to step Curation: 000188
- to stream Istex, to step Checkpoint: 000C98
Links to Exploration step
ISTEX:822D69D8AF997B918C96F2C5BBE698DBEF342BCBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant</title>
<author><name sortKey="Dillon, Susan B" sort="Dillon, Susan B" uniqKey="Dillon S" first="Susan B." last="Dillon">Susan B. Dillon</name>
</author>
<author><name sortKey="Demuth, Sandra G" sort="Demuth, Sandra G" uniqKey="Demuth S" first="Sandra G." last="Demuth">Sandra G. Demuth</name>
</author>
<author><name sortKey="Schneider, Mark A" sort="Schneider, Mark A" uniqKey="Schneider M" first="Mark A." last="Schneider">Mark A. Schneider</name>
</author>
<author><name sortKey="Weston, Cynthia B" sort="Weston, Cynthia B" uniqKey="Weston C" first="Cynthia B." last="Weston">Cynthia B. Weston</name>
</author>
<author><name sortKey="Jones, Christopher S" sort="Jones, Christopher S" uniqKey="Jones C" first="Christopher S." last="Jones">Christopher S. Jones</name>
</author>
<author><name sortKey="Young, James F" sort="Young, James F" uniqKey="Young J" first="James F." last="Young">James F. Young</name>
</author>
<author><name sortKey="Scott, Miller" sort="Scott, Miller" uniqKey="Scott M" first="Miller" last="Scott">Miller Scott</name>
</author>
<author><name sortKey="Bhatnaghar, Pradip K" sort="Bhatnaghar, Pradip K" uniqKey="Bhatnaghar P" first="Pradip K." last="Bhatnaghar">Pradip K. Bhatnaghar</name>
</author>
<author><name sortKey="Locastro, Stephen" sort="Locastro, Stephen" uniqKey="Locastro S" first="Stephen" last="Locastro">Stephen Locastro</name>
</author>
<author><name sortKey="Hanna, Nabil" sort="Hanna, Nabil" uniqKey="Hanna N" first="Nabil" last="Hanna">Nabil Hanna</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:822D69D8AF997B918C96F2C5BBE698DBEF342BCB</idno>
<date when="1992" year="1992">1992</date>
<idno type="doi">10.1016/0264-410X(92)90369-U</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-25G4G6FX-B/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000188</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000188</idno>
<idno type="wicri:Area/Istex/Curation">000188</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C98</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C98</idno>
<idno type="wicri:doubleKey">0264-410X:1992:Dillon S:induction:of:protective</idno>
<idno type="wicri:Area/Main/Merge">002043</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant</title>
<author><name sortKey="Dillon, Susan B" sort="Dillon, Susan B" uniqKey="Dillon S" first="Susan B." last="Dillon">Susan B. Dillon</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Anti-Infectives, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demuth, Sandra G" sort="Demuth, Sandra G" uniqKey="Demuth S" first="Sandra G." last="Demuth">Sandra G. Demuth</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Anti-Infectives, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schneider, Mark A" sort="Schneider, Mark A" uniqKey="Schneider M" first="Mark A." last="Schneider">Mark A. Schneider</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Anti-Infectives, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Weston, Cynthia B" sort="Weston, Cynthia B" uniqKey="Weston C" first="Cynthia B." last="Weston">Cynthia B. Weston</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Anti-Infectives, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jones, Christopher S" sort="Jones, Christopher S" uniqKey="Jones C" first="Christopher S." last="Jones">Christopher S. Jones</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Protein Biochemistry, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Young, James F" sort="Young, James F" uniqKey="Young J" first="James F." last="Young">James F. Young</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Protein Biochemistry, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Scott, Miller" sort="Scott, Miller" uniqKey="Scott M" first="Miller" last="Scott">Miller Scott</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Protein Biochemistry, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhatnaghar, Pradip K" sort="Bhatnaghar, Pradip K" uniqKey="Bhatnaghar P" first="Pradip K." last="Bhatnaghar">Pradip K. Bhatnaghar</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Peptidomimetic Research, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Locastro, Stephen" sort="Locastro, Stephen" uniqKey="Locastro S" first="Stephen" last="Locastro">Stephen Locastro</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Peptidomimetic Research, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hanna, Nabil" sort="Hanna, Nabil" uniqKey="Hanna N" first="Nabil" last="Hanna">Nabil Hanna</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Molecular Genetics, Research and Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Vaccine</title>
<title level="j" type="abbrev">JVAC</title>
<idno type="ISSN">0264-410X</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1992">1992</date>
<biblScope unit="volume">10</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="309">309</biblScope>
<biblScope unit="page" to="318">318</biblScope>
</imprint>
<idno type="ISSN">0264-410X</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active immunization</term>
<term>Adjuvant</term>
<term>Aluminium</term>
<term>Aluminium adjuvant</term>
<term>Aluminium hydroxide</term>
<term>Aluminium hydroxide adjuvant</term>
<term>Amino acids</term>
<term>Antibody responses</term>
<term>Antigenic drift</term>
<term>Antiviral memory</term>
<term>Assay</term>
<term>Baylor college</term>
<term>Bold type</term>
<term>Booster injection</term>
<term>Braciale</term>
<term>Cb6f</term>
<term>Cell response</term>
<term>Chromium release assay</term>
<term>Complete adjuvant</term>
<term>Control group</term>
<term>Control mice</term>
<term>Cytotoxic</term>
<term>Effector</term>
<term>Effector cells</term>
<term>Eliciting protection</term>
<term>Epitope</term>
<term>Epitope peptide</term>
<term>Escherichia coli</term>
<term>Human influenza</term>
<term>Hydroxide</term>
<term>Immune</term>
<term>Immune response</term>
<term>Immune sera</term>
<term>Immunization</term>
<term>Immunol</term>
<term>Influenza</term>
<term>Influenza vaccine</term>
<term>Influenza virus cytotoxic</term>
<term>Influenza virus vaccines</term>
<term>Ldso doses</term>
<term>Lethal challenge</term>
<term>Limited number</term>
<term>Lymph node cells</term>
<term>Lymphocyte</term>
<term>Major histocompatibility</term>
<term>Mice vaccinated</term>
<term>Microtitre wells</term>
<term>Monoclonal antibody</term>
<term>Mouse</term>
<term>Neutralizing</term>
<term>Neutralizing antibodies</term>
<term>Neutralizing antibody</term>
<term>Other studies</term>
<term>Outbred mice</term>
<term>Passive transfer</term>
<term>Peptide</term>
<term>Percentage lysis</term>
<term>Protective efficacy</term>
<term>Protective immunity</term>
<term>Protein</term>
<term>Protein control</term>
<term>Recombinant</term>
<term>Recombinant influenza vaccine</term>
<term>Recombinant nucleoprotein</term>
<term>Single injection</term>
<term>Soluble proteins</term>
<term>Spleen</term>
<term>Splenic</term>
<term>Splenic memory</term>
<term>Subunit</term>
<term>Synthetic peptide</term>
<term>Target cells</term>
<term>Target ratio</term>
<term>Target ratio figure</term>
<term>Third injection</term>
<term>Uninfected target cells</term>
<term>Unpublished results</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Various times</term>
<term>Virus</term>
<term>Virus challenge</term>
<term>Weeks post</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Induction of class I MHC-restricted cytotoxic T lymphocyte (CTL) responses by soluble proteins or peptides requires complex adjuvants or carrier systems which are not licensed for use with human vaccines. The data presented in this report show that vaccination with a highly purified recombinant influenza protein antigen in aluminium hydroxide adjuvant, the only adjuvant currently licensed for clinical use, elicited class I restricted CTL and protection from lethal challenge with H1N1 and H2N2 viruses. The antigen (D protein, SK&F 106160) is produced by expression of H1N1 influenza virus-derived cDNA (strain A/PR/8/34) in Escherichia coli, and is composed of the first 81 N-terminal amino acids (aa) of the non-structural protein 1 (NS1) fused via a nine nucleotide non-viral linker sequence to the 157 C-terminal aa of the haemagglutinin 2 subunit (HA2). Previous work by Kuwano et al demonstrated that in vitro stimulation of spleen cells from influenza virus-primed mice, with a partially purified preparation of the D protein, selected for CD8− CTL clones which facilitated lung clearance of H1N1 and H2N2 viruses. In the current study, these results were extended by studying the responses of mice actively immunized with highly purified D protein in the presence or absence of adjuvants. Vaccination of CB6F1 (H-2d × b) mice with D protein in aluminium hydroxide or Freund's complete adjuvant generated H1N1 cross-reactive, H-2d-restricted, CD8+ CTL directed against an immunodominant HA2 epitope (aa 189–199). D protein without adjuvant did not elicit CTL, regardless of the route of injection. However, long-lived (>6 months) splenic memory CTL were elicited by boosting mice intraperitoneally (i.p.) with the D protein in the absence of adjuvant. In mice injected subcutaneously with D protein in aluminium hydroxide at weeks 0 and 3, survival was increased relative to controls up to 16 weeks beyond the second vaccination, after which time additional boosting was required for protection. Studies in H-2b and H-2k mice vaccinated with the D protein showed that induction of CD4+ T-cell or antibody responses, in the absence of CD8+ CTL, did not correlate with protection. Passive transfer of immune sera from CB6F1 mice was also not protective. This prototype H1N1 recombinant subunit vaccine in aluminium adjuvant should directly address the feasibility of achieving a protective cell-mediated immune response in human influenza.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002043 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002043 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:822D69D8AF997B918C96F2C5BBE698DBEF342BCB |texte= Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant }}
This area was generated with Dilib version V0.6.33. |